| Literature DB >> 29694546 |
Yu Kang1, Fei Xiao1, Haiyan Chen2, Wei Wang1, Lijing Shen1, Hang Zhao1, Xuedong Shen1, Fangyuan Chen1, Ben He1.
Abstract
BACKGROUND: Anthracycline generates progressive left ventricular dysfunction associated with a poor prognosis.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29694546 PMCID: PMC5898770 DOI: 10.5935/abc.20180042
Source DB: PubMed Journal: Arq Bras Cardiol ISSN: 0066-782X Impact factor: 2.000
Clinical characteristics of two groups
| Normal | Chemotherapy | p value | |
|---|---|---|---|
| Number | 27 | 42 | |
| Male (n/%) | 12 (44.44) | 18 (42.86) | 0.84 |
| Age (y) | 50.39 ± 13.40 | 55.83 ± 17.92 | 0.16 |
| Hypertension (n/%) | 0(0) | 4(9.52) | |
| ACEI (n/%) | 0(0) | 1(2.38) | |
| ARB (n/%) | 0 (0) | 1(2.38) | |
| CCB (n/%) | 0(0) | 0(0) | |
| β-blocker (n/%) | 0(0) | 1(2.38) | |
| Smoker (n/%) | 5(17.24) | 9(21.42) | 0.470 |
| DM (n/%) | 0(0) | 1(2.38) | |
| SBP (mmHg) | 124.8 ± 12.6 | 121.6 ± 12.5 | 0.627 |
| DBP (mmHg) | 70.7 ± 9.3 | 69.5 ± 7.9 | 0.233 |
| HR (bpm) | 78.0 ± 11.3 | 81.0 ± 14.5 | 0.099 |
ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blockers; CCB: calcium-channel blocker; DBP: diastolic blood pressure; DM: diabetes mellitus; HR: heart rate; SBP: systolic blood pressure; p values were assessed by independent samples t test
Conventional echocardiographic parameters between two groups.
| Normal | Chemotherapy | p value | |
|---|---|---|---|
| LVEDV/BSA (ml) | 47.22 ± 13.97 | 46.99 ± 13.99 | 0.95 |
| LVESV/BSA (ml) | 16.31 ± 6.24 | 16.30 ± 6.47 | 0.99 |
| LVMI (g/m2) | 79.32 ± 16.66 | 71.87 ± 13.68 | 0.13 |
| RWT | 0.36 ± 0.05 | 0.36 ± 0.05 | 0.93 |
| LVEF (%) | 66.46 ± 5.55 | 66.04 ± 6.52 | 0.78 |
| E velocity (m/s) | 80.38 ± 24.11 | 72.45 ± 16.99 | 0.11 |
| A velocity (m/s) | 76.62 ± 17.76 | 76.61 ± 19.07 | 0.95 |
| E/A ratio | 1.11 ± 0.44 | 1.01 ± 3.53 | 0.32 |
| S' velocity (m/s) | 9.50 ± 2.19 | 9.24 ± 2.08 | 0.60 |
| E/E' ratio | 6.95 ± 3.21 | 6.71 ± 2.31 | 0.71 |
| DT (ms) | 145.88 ± 27.81 | 149.95 ± 34.28 | 0.61 |
| IVRT (ms) | 85.36 ± 20.14 | 88.13 ± 24.77 | 0.62 |
BSA: body surface area; DT: deceleration time; FS: fraction shortening; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESV: left ventricular end-systolic volume; LVMI: left ventricular mass index; IVRT: isovolumic relaxation time; RWT: relative wall thickness; p values were assessed by independent samples t test
Three-layer circumferential strain values between two groups stratified by levels
| CS-Endo(%) | CS-Mid(%) | CS-Epi(%) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Control | Chemotherapy | P value | Control | Chemotherapy | P value | Control | Chemotherapy | p value | |
| Basal level | -33.48 ± 5.10 | -26.26 ± 4.34 | 0.000 | -23.95 ± 4.26 | -22.37 ± 4.28 | 0.149 | -17.58 ± 4.03 | -16.85 ± 3.93 | 0.453 |
| Mid level | -34.29 ± 4.21 | -31.25 ± 5.39 | 0.014 | -24.45 ± 3.46 | -22.57 ± 3.67 | 0.053 | -17.54 ± 3.21 | -16.85 ± 3.94 | 0.063 |
| Apical level | -44.31 ± 6.14 | -41.13 ± 9.47 | 0.038 | -30.32 ± 4.46 | -28.91 ± 6.34 | 0.316 | -21.77 ± 3.95 | -19.81 ± 5.39 | 0.105 |
| P value | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||
CS-ENDO: subendocardial circumferential strain; CS-EPI: subepicardial circumferential strain; CS-MID: middle circumferential strain. P values were analyzed by one way ANOVA test.
Three-layer longitudinal strain values between two groups stratified by levels
| LS-Endo(%) | LS-Mid(%) | LS-Epi(%) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Control | Chemotherapy | P value | Control | Chemotherapy | P value | Control | Chemotherapy | p value | |
| Basal level | -18.51 ± 2.55 | -16.82 ± 2.36 | 0.006 | -17.74 ± 2.50 | -16.49 ± 2.11 | 0.027 | -17.07 ± 2.50 | -15.63 ± 2.00 | 0.009 |
| Mid level | -22.76 ± 2.72 | -21.04 ± 2.87 | 0.014 | -20.82 ± 2.39 | -19.45 ± 2.49 | 0.028 | -19.23 ± 2.56 | -16.87 ± 2.26 | 0.000 |
| Apical level | -34.36 ± 3.23 | -32.29 ± 5.69 | 0.101 | -26.20 ± 3.06 | -25.08 ± 4.23 | 0.623 | -20.8 ± 2.55 | -19.53 ± 5.12 | 0.538 |
| P value | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||
LS-ENDO: subendocardial longitudinal strain; LS-EPI: subepicardial longitudinal strain; LS-MID: middle longitudinal strain. P values were analyzed by one way ANOVA test.
Strain values between two groups.
| Control | Chemotherapy | p value | |
|---|---|---|---|
| GLS (%) | -21.86 ± 2.38 | -20.36 ± 2.58 | 0.016 |
| GCS (%) | -27.73 ± 3.37 | -24.94 ± 4.14 | 0.004 |
| GRS (%) | 31.44 ± 12.98 | 26.89 ± 9.75 | 0.118 |
| LS-ENDO(%) | -25.21 ± 2.72 | -23.38 ± 3.11 | 0.014 |
| LS-MID(%) | -21.53 ± 2.36 | -20.35 ± 2.58 | 0.029 |
| LS-EPI(%) | -18.83 ± 2.19 | -17.35 ± 2.48 | 0.013 |
| LS gradient (%) | -6.38 ± 1.28 | -6.03 ± 2.07 | 0.439 |
| CS-ENDO(%) | -37.37 ± 3.79 | -32.88 ± 5.23 | 0.000 |
| CS-MID(%) | -26.24 ± 2.98 | -24.62 ± 4.13 | 0.073 |
| CS-EPI(%) | -19.56 ± 4.45 | -17.32 ± 4.13 | 0.066 |
| CS gradient(%) | -17.80 ± 3.69 | -15.55 ± 4.59 | 0.0 |
CS-ENDO: subendocardial circumferential strain; CS-EPI: subepicardial circumferential strain; CS-MID: middle circumferential strain; GCS: global circumferential strain; GLS: global longitudinal strain; GRS: global radial strain; LS-ENDO: subendocardial longitudinal strain; LS-EPI: subepicardial longitudinal strain; LS-MID: middle longitudinal strain.
p < 0.05. p values were assessed by independent samples t test
Figure 1 Strain values between two groups. *:p < 0.05.
Figure 2Bland-Altman analysis of inter-, intra-observation reproducibility.